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Lung cancer remains a significant public health problem in 2006, despite efforts aimed at 
educating individuals about the dangers of tobacco and the successes of smoking cessation 
programs.  No screening methods aimed at high risk individuals are currently supported by the 
National Cancer Institute or other medical organizations.  Since the risk for lung cancer persists 
even after smoking cessation, studies of methods to detect lung cancer in its early stages, when it 
is amenable to cure, are clearly needed. 
This study examined a novel method of sputum collection and processing to determine 
whether the adequacy of the samples collected was improved over conventional preparation 
methods.  We also examined lung function as a possible predictor of cytologic abnormality in the 
sputum of individuals at high risk for lung cancer, and studied the potential of a molecular 
biomarker for the early detection of lung cancer.  This study employed a cross-sectional design 
and utilized quantitative methods for exploring the relationships between the variables, 
particularly those of lung function, cytologic diagnosis and gene mutation status, with personal 
risk factors for developing lung cancer. 
This study demonstrated an association between lung function and cytologic diagnosis of 
moderate or worse atypia in the sputum collected from these participants and examined at the 
University of Colorado.  We also demonstrated a higher rate of sputum specimen adequacy than 
iv 
has been previously reported from conventional clinical experience.  We examined the feasibility 
of conducting somatic gene mutation analysis on the samples collected by this novel method.  
We achieved some success in studying K-ras mutations, but were unsuccessful in our analysis of 
DNA methylation.  From these experiences, we have gathered information upon which to base 
further studies. 
The importance of these findings from a public health perspective is that there is an 
opportunity for early detection of lung cancer via analysis of cellular and molecular changes in 
sputum.  We have demonstrated that the Thin Prep® methodology, applied to sputum, produces 
material suitable for cytologic examination and, under certain circumstances, material suitable 
for molecular analysis. Patients at high risk for lung cancer will benefit from continued research 
into novel screening methods.  
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 1. INTRODUCTION 
 
1.1. Introduction 
It is expected that an estimated 174,470 new cases of lung cancer will be diagnosed in 2006, 
accounting for 12% of new cancer diagnoses.  While the incidence rates of lung cancer have 
been declining significantly in men since its peak in 1984, in women, the rates have been stable 
since 1998, after a long period of increase (American Cancer Society, 2006). 
Lung cancer is the leading cause of cancer death in both men and women, with 162,460 
deaths predicted in 2006.  Death rates in men have been falling since 1991 at a rate of about 
1.8% per year. In women, death rates have been virtually unchanged since 1995. Although rates 
are declining, lung cancer kills more African American men than any other cancer, with 15,500 
deaths expected in 2005. Rates in women have stabilized since 1998 (American Cancer Society, 
2005).  Decreasing lung cancer incidence and mortality rates reflect decreased smoking rates 
over the past 30 years. 
The five-year relative survival rate for all lung cancer stages combined is only 15%.  For 
localized disease, this rate is 49%; however, only 16% of all lung cancer cases are diagnosed at 
this early stage.  African Americans with Stage I or II non-small cell lung cancer are less likely 
to receive surgery than whites of the same income level, even if they have health insurance.  This 
disparity accounts for much of the difference in survival rates (Ward et al., 2004). 
About 50 percent of adults in the United States have smoked; half of them have quit.  
After smoking cessation, the risk of coronary artery disease drops immediately, whereas the risk 
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of lung cancer does not.  Therefore lung cancer has recently replaced coronary artery disease as 
the leading cause of death among current and former smokers (Mulshine & Sullivan, 2005). 
Although no major medical professional organization recommends screening for lung 
cancer at this time, recent studies show that CT scanning can diagnose lung cancer at an earlier 
stage than in usual clinical practice.  Unfortunately, at this time little is known about clinical 
outcomes.  Both false negative results, resulting in false assurance, and false positive results, 
with ensuing anxiety, further costs, and risk from additional testing are issues.  
Sputum cytology offers a low cost and relatively simple method for screening for lung 
cancer and also for stratifying individuals at risk for developing lung cancer over a period of 
years.  Sputum cytology may be especially helpful for detecting central airway lesions, although 
it has some of the same limitations as CT screening, particularly that of false negative and false 
positive results.  Because of limitations, sputum cytology is seldom used for screening of 
individuals at high risk for developing lung cancer outside of research studies.  Some clinicians 
utilize sputum cytology for diagnostic purposes when lung cancer is suspected, however, no 
consensus exists about the role of diagnostic sputum cytology.  Studies of sputum for several 
promising biomarkers related to lung cancer are underway.  These studies may lead to new 
methods of screening for lung cancer and predicting which individuals are at increased risk. 
This study examined the sputum of 154 participants enrolled in the Pittsburgh Lung 
Screening Study (PLuSS), a large CT screening study of individuals at high-risk for developing 
lung cancer.  Sputum was collected for cytology and gene mutation studies. These findings were 
examined in relation to lung function and baseline data including smoking history, age, and 
gender to determine the relationships between these variables.   
2 
1.2. Specific Aims 
The larger objective of this activity is to evaluate two biomarkers, sputum cytology and 
somatic K-ras mutations in sputum, processed according to a novel method of slide 
preparation, the ThinPrep® 2000 system. 
The aims of this project are: 1) to determine the adequacy of sputum collected 
within the context of the Pittsburgh Lung Screening Study (PLuSS), Molecular 
Epidemiology of CT Detected Lung Cancer; processed using the ThinPrep® method; 2) 
to determine if mean forced expiratory volume in the first second (FEV1) is associated 
with atypia; 3) to determine if baseline measures other than FEV1 are associated with 
cytologic atypia; 4) to determine the prevalence of K- ras mutations in the sputum of 
persons at risk for lung cancer and; 5) to quantify the sensitivity and specificity of FEV1 
to predict atypia. 
 
 
 
 
 
 
 
3 
  
 
 
 
2. LITERATURE REVIEW 
 
2.1. Background and Current State of Lung Cancer Screening 
2.1.1. Early Studies 
Randomized studies to date have failed to demonstrate that early detection of lung cancer 
decreases mortality.  Three National Cancer Institute (NCI) sponsored studies conducted in the 
US in the 1970s and 1980s, at Mayo Clinic, Johns Hopkins Oncology Center, and Memorial 
Sloan-Kettering Cancer Center (MSKCC), and one in Czechoslovakia, failed to show a 
reduction in mortality with sputum cytology and interval chest radiographs.  These studies have 
been criticized for being underpowered based on current knowledge of high risk, for the quality 
of sputum evaluations and for low compliance (Fontana, 2000; Kennedy et al., 2000; Petty, 
2000).  None of these screening studies included women; therefore it is impossible to know if 
the negative results applied only to men (Gazdar & Minna, 1999). Despite these flaws, and 
despite improvement in laboratory techniques and significant advances in cancer biology since 
these studies were conducted, neither the American Cancer Society nor the NCI recommends 
early stage screening for lung cancer at this time.  In both 1985 and 1996, the U.S. Preventative 
Services Task Force (USPSTF) gave lung cancer screening a grade D recommendation, meaning 
there are fair-quality data indicating that screening for lung cancer may not be effective 
(Humphrey et al., 2004).  
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 2.1.2. Current State of Lung Cancer Screening 
In 2004, the  USPSTF concluded that the evidence is insufficient to recommend for or against 
screening asymptomatic persons for lung cancer with either low dose computerized tomography 
(LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests. (U.S. Preventive 
Services Task Force Screening for Lung Cancer. Release Date: May 2004). 
Presently, sputum cytological testing is infrequently ordered before the implementation 
of invasive diagnostic techniques, even in patients with central lung masses, despite its 
noninvasiveness and low cost (Raab et al., 1997). In laboratories where sputum cytology is 
routinely carried out by well-trained and experienced cytotechnologists, sensitivity to detect lung 
cancer is projected to be 20-30% at best (Palcic et al., 2002), although it is often much lower, 
with specificity at 99%.  Sensitivity is much worse for very early lung cancers, and for peripheral 
tumors.  Researchers are re-visiting the clinical utility of sputum cytology and are studying new 
and promising biomarkers to identify people who could benefit from more extensive diagnostic 
examination (Prindiville et al., 2003). 
 
2.2. Risk Factors for Developing Lung Cancer 
2.2.1. Cigarette Smoking 
Cigarette smoking is the cause of approximately 90% of all lung cancers (Hecht et al., 2004).  
Although epidemiologic evidence first linked smoking and lung cancer in the 1950s, more recent 
studies also link tobacco smoke with several other cancers including myeloid leukemia, and 
cancer of the stomach, liver, kidney and cervix (Leischow & Djordjevic, 2004; Vineis et al., 
2004). One in ten smokers will develop lung cancer over a lifetime (Siegfried, 1999). The risk of 
lung cancer remains elevated even 15 years after smoking cessation (Mulshine et al., 1997). 
5 
 Among smokers, airway obstruction is more of an indicator for the development of lung cancer 
than age or the level of smoking (Tockman et al., 1987). 
2.2.2. Environmental and Occupational Risk Factors 
Although most cases of lung cancer in the U.S. and worldwide can be attributed to cigarette 
smoking, lung cancer is also caused by environmental factors and occupational exposures.  There 
is some evidence that asbestos, environmental cigarette smoke, and radon decay products are 
occupational carcinogens in nonsmokers (Neuberger & Field, 2003).  However, little data exist 
concerning occupational carcinogens in women.  Ambient air pollution and indoor air pollution 
are cited as environmental factors, which contribute to the development of lung cancer.  As 
genetic determinants to lung cancer susceptibility are better understood and early indicators of 
the carcinogenic actions of these environmental and occupational agents are better known, 
preventive steps can be taken to reduce these risks (Samet, 2004). 
2.2.3. Obstructive Lung Disease and Lung Cancer 
Decreased pulmonary function is associated with both the risk of developing lung cancer and 
with lung cancer mortality in smokers and those who have quit smoking (Eberly et al., 2003; 
Tockman et al., 1987; Mannino et al., 2003; Kennedy et al., 1996; Prindiville et al., 2003).  In 
these studies, pulmonary function was assessed through measurements of Forced Expiratory 
Volume in one second (FEV1), Forced vital capacity (FVC) and FEV1/FVC ratio. Two of these 
studies utilized sputum cytology evaluation. A study of patients with airflow obstruction and a 
40-plus pack year smoking history showed an association between airflow obstruction and a high 
prevalence of sputum-detected premalignant dysplasia (Kennedy et al., 1996).  In another high-
risk cohort, defined as chronic obstructive pulmonary disease detected by pulmonary function 
testing, and a smoking history of 30 pack years or more, sputum cytologic atypia of moderate or 
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 worse grades was associated with incident lung cancer (Prindiville et al., 2003).  Screening for 
lung cancer in patients with documented airway obstruction, utilizing modern methods, should 
find many cancers at an early stage, when they will be amenable to cure (Petty, 2001). 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) developed a four 
stage classification system of COPD severity to assist physicians in determining therapeutic 
approaches.   In stage 0, patients are characterized by clinical symptoms of COPD but normal 
spirometry.  Stage I defines patients with FEV1/FVC of less than 70 and FEV1 of > 80% 
predicted, with or without the presence of symptoms. Stage II includes patients with 
FEV1/FVC<70, FEV1 30-79 and is split into two substages, IIa (FEV1 50-79%) and IIb (FEV1 
30-49%), with IIb being more inversely related to health status.  In Stage III, FEV1/FVC is 
<70% and either FEV1 <30% predicted, hypoaxemia, or clinical signs of heart failure exist.  
Stage III is expected to be associated with the worst health status (Mannino et al., 2003; 
Antonelli-Incalzi et al., 2003). 
 
2.3. Lung Cancer Screening in the U.S. 
Currently, most individuals in the U.S. are not screened for lung cancer.  However, because data 
are limited and trials have not compared screening with no screening, or screening of women, the 
issue of lung cancer screening is being reevaluated (Humphrey et al., 2004).  Routine yearly 
chest radiography is being compared with usual care in the large, multicenter Prostate, Lung, 
Ovarian and Colorectal Cancer (PLCO) trial, in which 154,938 men and women age 55 and older 
were enrolled.  Data from the PLCO trial should be available in 2010.   
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 2.3.1. Low-dose Spiral CT Screening 
Studies are ongoing to determine the role of spiral CT screening in early detection of lung 
cancer.  Spiral CT imaging takes 15 to 30 seconds, allowing complete imaging in one breath 
hold.  This procedure has the radiation exposure of a mammogram, and can detect lesions as 
small as 2 to 3 mm in size (Kennedy et al., 2000).  Over identification of benign lesions from 
spiral CT screening is a concern, leading to possible morbidity from over treatment (Sabue et al., 
2002; Swensen et al., 2002).  Initial results of a groundbreaking study were published in 1999 by 
the Early Lung Cancer Action Project (ELCAP). This trial enrolled 1000 asymptomatic men and 
women, sixty years of age and older, with at least a 10 pack-years cigarette smoking history. 
ELCAP investigators used conventional chest x-ray and low-radiation-dose computerized 
tomography (low-dose CT) to detect early lung cancer.  These results changed the thinking of the 
medical community in regards to lung cancer screening and have stimulated interest in the role 
of low-dose CT scan screening as an early detection tool. In ELCAP, low-dose CT detected lung 
cancer four times more often than chest x-ray (2.7% vs. 0.7%). And did not miss any lung cancer 
detected by chest x-ray. Twenty-six of 27 CT-detected lung cancers were surgically resected. 
Screening CT was frequently abnormal (23.3%). However, only four subjects had a negative 
lung biopsy because of a CT abnormality. Three of these four circumvented the ELCAP 
diagnostic protocol (Henschke et al., 1999). 
Currently a large trial, the National Lung Screening Trial (NLST), sponsored by the 
National Cancer Institute, is comparing routine spiral chest CT scanning with chest radiography 
in high risk men and women 55 to 74 years of age. By February 2004, nearly 50,000 current or 
former smokers were enrolled in NLST at more than 30 study sites across the country. The trial, 
now closed to further enrollment, is slated to collect and analyze data for eight years. 
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 2.3.2. Pittsburgh Lung Screening Study (PluSS) 
The University of Pittsburgh Cancer Institute has recently completed recruitment for a large lung 
cancer screening study using low-dose computerized tomography (CT) to find early lung cancer 
in current and ex-smokers, and laboratory methods to explore the molecular epidemiology of 
lung cancer.  The research aim was to recruit 6000, 50-79 year-old men and women at-risk for 
lung cancer by virtue of current or past cigarette smoking history.  In April 2005, the study 
ceased enrollment with a total accrual of 3755 participants.  In addition to low-dose CT scan 
screening, investigators collected baseline questionnaire data, collected blood and conducted 
pulmonary function  studies.  Most patients have recently completed the one-year CT screening.  
To ascertain lung cancer endpoints, the investigators will track research participants for at least 
two years and match cohort members against the Pennsylvania state-wide cancer incidence 
registry.  Serum and genomic DNA collected from subjects found to have lung cancer and from 
age-gender matched subjects without lung cancer will be examined for established or novel lung 
cancer risk or susceptibility factors. 
 
2.4. SPUTUM CYTOLOGY 
Sputum cytology has long been considered a first step in lung cancer diagnosis, because it is 
inexpensive and noninvasive, although its use has waned in recent years.  Sputum cytology 
studies can identify dysplasia, carcinoma in situ, and invasive cancer, relying on the skill of the 
cytopathologist and adequacy of the specimen for interpreting the results.  Recent advances such 
as automated technology have improved the sensitivity and specificity of sputum cytology 
(Payne et al., 1997), while thin layer technologies have improved specimen adequacy. At the 
University of Pittsburgh, our technique for evaluation of sputum for cytologic changes carries a 
9 
 high degree of specificity.  The University of Colorado Lung SPORE utilizes a validated 
technique for evaluating sputum cytology which is based upon documented research on 
outcomes, particularly the risk for developing lung cancer over a period of years.  A study of 
2006 participants at the University of Colorado showed little association between lung cancer 
risk and mild atypia (adjusted risk 1.10), but an increase in incident lung cancer in participants 
with moderate atypia (adjusted risk 1.68), in those with moderate atypia and worse (adjusted risk  
3.18), and a considerably elevated adjusted risk (31.4) in participants with greater than moderate 
atypia (Prindiville et al., 2003). In a recently published retrospective analysis of a group of 79 
individuals at the University of Colorado with moderate sputum atypia, airflow obstruction, 
heavy tobacco exposure and negative chest radiography, 5 subjects were diagnosed with lung 
cancer on combined autofluorescence and white light bronchoscopy (Kennedy et al., 2005).  
In the Johns Hopkins Lung Project, 86 of 626 (14%) of participants with moderate sputum atypia 
or worse later progressed to lung cancer, compared with 147 of 4600 (3%) of participants 
without atypia (Prindiville et al., 2003).   
In our study, two highly-regarded cytopathology groups interpreted sputum cytology utilizing 
different evaluation criteria, and with different outcomes.  This provides justification for 
investigating other biomarkers, such as K-ras mutations, and their association with cytologic 
abnormality and baseline characteristics of our participants. 
2.4.1. Conventional Sputum Collection and Preparation 
The conventional method of sputum collection, most commonly used in studies of sputum 
cytology, involves collecting specimens in a solution of 2% carbowax and 50% ethyl alcohol 
(Saccomanno’s fixative).  Traditionally, the slides are prepared manually by the 
cytotechnologist, using the “pick and smear” technique (Rana et al., 2001).  A sputum sample is 
10 
 considered representative when pulmonary macrophages or bronchial epithelial cells are present 
as these features demonstrate a sample from deep within the lung (Thunnissen, 2003).  The 
conventional method has been criticized for problems such as cell overlapping and background 
debris, as well as slides that are too scanty, too thin or too thick. 
2.4.2. ThinPrep® 2000 Technology 
The conventional method of preparing slides for cytolologic analysis involves challenges, 
particularly in determining the optimal amount of material per slide.  New technologies, such as 
the ThinPrep® 2000 system, have been developed in recent years to improve both sample 
collection and cytopreparation.  This study uses the ThinPrep® 2000 system (Cytyc 
Corporation).  Specimens are collected in CytoLyt® solution, and then first processed by 
centrifuging the specimen for 10 minutes, then decanting the supernatant. A stock solution of 2.5 
G Dithiothreitol (DTT) and 30 ml of CytoLyt® is prepared and approximately 2 ml of the 
solution is added to each specimen to achieve mucolysis.  Next, the specimens are vortexed to 
break up the mucus and CytoLyt® is added to each specimen. Again the specimens are 
centrifuged for 10 minutes to concentrate the cellular material.  The supernatant is decanted and 
the specimens are vortexed to dislodge the cell pellet.  Finally, two drops of the specimen are 
added to a vial of PreservCyt® solution.  The material is run on the ThinPrep® 2000 processor 
using setting three (mucoid specimens) (Cytyc Corporation Operator’s Manual).  The ThinPrep® 
processor software system controls the cellular density by continuously monitoring the flow rate 
across a filter membrane to ensure that an appropriate number of cells are collected (Linder, 
1998).  This method greatly reduces the number of unsatisfactory specimens (Fischler & Toddy, 
1996; Leung et al., 1998; Rana et al., 2001), which can compromise diagnostic accuracy.  
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 2.4.3. Automated Technologies for Sputum Examination 
Studies have been ongoing in Vancouver in collaboration with several other centers regarding 
the usefulness of high-resolution image cytometry (McWilliams et al., 2003; Palcic et al., 2002; 
Payne et al., 1997; Tockman, 2000). This method is based on the principles of quantitative 
cytology, where measurements of nuclear features of selected cells in sputum are made, using 
computer-assisted image cytometry.  This approach has two unique aspects.  The first is the 
characterization of atypical cells, if any, as to whether or not they are cancerous.  The second 
aspect involves the characterization of normal appearing diploid lung epithelial cells.  The cell 
populations of individuals with lung cancer show what is described as malignancy appearing 
changes (MACs), as compared to those without lung cancer. Research efforts to better 
understand MACs are underway. Current literature suggests that high-resolution image 
cytometry can improve sensitivity of detection of adenocarcinoma to 60% (at 90% specificity) 
and to 45% for stages 0 and 1 lung cancer (at 90% specificity) (Palcic et al, 2002).  Further 
improvements of these techniques are needed before this test can be considered for screening of 
high-risk individuals for lung cancer. 
2.4.4. Sputum Collection Techniques 
Sputum based lung cancer screening tests face several fundamental limitations.  One limitation 
relates to the challenges associated with the collection of satisfactory sputum samples. Two 
common methods for sputum collection are induction, utilizing saline solution, and early 
morning spontaneous cough collection, done at home.   A study of these two sputum collection 
techniques utilized the following criteria to determine the adequacy of specimen collection: 
sufficient cells of deep lung origin which included carbon-laden histiocytes, ciliated columnar 
cells, goblet cells, macrophages, and Curschmann’s spirals, proper fixation of the specimen, 
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 absence of contamination, and minimal or no evidence of acute or chronic inflammation 
(Kennedy et al., 1999). In this study, one hundred seven people with chronic obstructive 
pulmonary disease (COPD) were randomly assigned to sputum collection by induction with 
hypertonic solution, done at the enrollment center, then sputum collection at home (three day 
pooled specimen) or the same two sputum collection methods in reverse order. Overall, there 
was no difference in the efficacy of collection between induced sputum, and sputum collected at 
home.  However, on average, the second specimen produced by a subject, whether produced 
spontaneously or by induction, was superior to the first specimen produced.  This was attributed 
to learning effect. This collection technique was used in several of the studies cited in this 
literature review. The advantages to using the at home collection in this study were lower cost 
and the convenience to the participants. 
 
2.5. Promising Biomarkers for Early Detection of Lung Cancer 
There is a relative paucity of highly promising well-validated markers to study in lung cancer.  
Researchers studied archived sputum specimens from subjects entered onto the Johns Hopkins 
study who later developed lung cancer.  Two promising monoclonal antibodies identified 
biomarkers of lung cancer in patients previously determined to be free of cancer.  One of these 
antibodies, MoAb 703D4, binds a heterogeneous nuclear riboprotein A2/B1, which has shown 
promise as a marker for early lung cancer in several studies (Mulshine, 1999); Petty, 2001; 
Tockman, 2000).  K- ras mutations have been found frequently in non-small cell lung cancers, 
particularly adenocarcinoma (Toshinari & Masayoshi, 2000) and may be detected in both tumor 
samples and in sputum (Zhang et al., 2003). In some studies the presence of K- ras has been 
associated with worse outcomes than those with tumors of the same stage but without K- ras 
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 mutation.  Other genetic mutations have been identified in lung cancer including allelic deletion 
or tumor suppressor gene inactivation in 3p, 5q, 9p, 11q, 17p, 13q, 18q, and 22q (Kennedy et al., 
2001).  The tumor suppressor gene P53 is frequently involved in carcinogenesis, with mutations 
seen in many cancers, including lung cancer (Kennedy et al., 1996; Kersting et al., 2000).  
Though detectable in sputum, P53 mutations are frequently seen in chronic smokers as well as 
patients with lung tumors and thus its specificity is not optimal (Kersting et al., 2000).  
2.5.1. DNA Methylation 
DNA methylation occurs at the CpG dinucleotides, which can be clustered in small stretches of 
DNA known as “CpG islands” (Baylin et al., 1998; Bird, 2002). These areas are often associated 
with the promoter regions, where transcription of DNA into RNA begins. Normally, 
unmethylated CpG islands appear protected from dense methylation seen in neighboring regions.  
In cancer cells, this protection is lost, although the exact mechanism is unknown.  In some genes, 
hypermethylation appears only after the onset of neoplastic evolution.  In other genes, such as 
the estrogen receptor, hypermethylation occurs normally during aging (Baylin et al., 1998; 
Herman et al., 1996). 
The biologic effects of the loss of gene function caused by promoter hypermethylation 
are very similar to that of coding region mutations (Herman & Baylin, 2003).  A coding region 
mutation can be the first hit in inherited cancer or sporadic cancer, whereas, silencing of gene 
transcription through promoter hypermethylation can be the first hit only in sporadic but not 
inherited cancers. Aberrant DNA methylation patterns have been found in either free DNA in 
plasma or serum, and in cells from bone marrow, sputum, blood, and other body fluids 
(Fruhwald, 2003). 
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 Researchers recently modified a polymerase chain reaction (PCR) technique to improve the 
sensitivity of detecting methylated alleles.  This method, the Methylation-specific PCR (MSP) 
assay, identified aberrant methylation of the p16 and/or O6-methylguanine-DNA 
methyltransferase promoters in DNA from sputum in 100% of patients with squamous cell lung 
carcinoma up to three years before clinical diagnosis (Baylin et al., 1998). 
2.5.2. Hypermethylation of the P16 Gene in Lung Cancer 
Recent studies have demonstrated that aberrant methylation of the p16 tumor suppressor gene is 
an early and frequent event in squamous cell carcinoma (SCC) of the lung (Belinsky et al., 1998; 
An et al., 2002; Palmisano et al., 2000).  Exposure to cigarette smoke may induce methylation of 
CpG islands (Kim et al., 2001).  Studies have shown hypermethylation of the p16 gene in 
chronic smokers before clinical evidence of neoplasia (Kersting et al., 2000; Lamy et al., 2002) 
and in individuals exposed to radon (Gilliland et al., 2002).  Tumor cells in which the p16 gene 
has been inactivated by hypermethylation may also be associated with progression and 
metastasis in patients with non-small cell lung cancer (Sieke et al, 2000).  
 
2.6. K-ras Gene Mutations in Lung Cancer 
The K-ras oncogene is frequently mutated in several types of human cancer (Somers et al., 
1998). In lung cancer, point mutations of the K-ras oncogene occur mainly at codon 12, with G 
to T transversion being the most common (Destro et al., 2003), and less commonly in codons 13 
and 61. These point mutations alter the structure of this gene, preventing inactivation and causing 
cell transformation (Graziano et al., 1999). 
K-ras mutations are more commonly found in adenocarcinomas (20-40%) than in other 
histological types. About 92% of these mutations occur at codon 12 (Camps et al., 2005).  Many 
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 studies of K-ras mutations in lung cancer focus on tumor samples.  However, K-ras mutations 
are also commonly found in plasma, sputum, and samples from Bronchoalveolar Lavage (BAL), 
making this marker useful for early detection of lung cancer. 
2.6.1. K-ras Gene Mutations and Cigarette Smoking 
Several studies have shown an association between K-ras mutations and cigarette smoking. 
Slebos, et al. looked at lung adenocarcinoma samples from 27 smokers and 27 nonsmokers for 
codon 12 K-ras mutations and found that these mutations occur more frequently in smokers but 
may also occur in nonsmokers (Slebos et al., 1991).  Westra et al. examined lung 
adenocarcinomas from current and former smokers and never smokers, and found no difference 
in the prevalence of mutations in codon 12 of K-ras from tissue from former and current 
smokers, but that the prevalence of these mutations was significantly greater than that in never 
smokers (Westra et al., 1993).  A more recent examination of lung tumors from women with 
lung cancer who were never smokers, occasional smokers, and lifetime smokers showed K-ras 
mutations to be more common in the lifetime smoking group; however the same types of K-ras 
mutations were seen in both groups (Gealy et al., 1999). Ahrendt et al. recently studied the 
primary tumors of 106 patients undergoing surgical resection for primary adenocarcinoma, 92 of 
whom were smokers. K-ras mutations were detected on 40 of these tumors (38%) and were 
significantly more common in smokers than nonsmokers (Ahrendt et al., 2001). 
Although the association between smoking and K-ras mutation is strong throughout the 
literature, a comparison of long-term ex-smokers (9) and nonsmokers (177) with lung cancer 
revealed no differences in the prevalence (11% in both groups) of codon 12 or 13 K-ras 
mutations (Vahakangas et al., 2001). 
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 2.6.2. K-ras Gene Mutations and the Association with Prognosis in Patients with Lung 
Cancer 
 
Several studies have reported an association between K-ras mutations and poorer survival rates. 
Studies have associated K-ras mutations with larger tumors, more frequent lymph node 
metastases and shorter survival when compared with patients with wild-type K-ras (Cho et al., 
1997; Fukuyama et al., 1997; Slebos et al., 1990), although these findings have not been 
consistent.  
Slebos et al. examined tumors from resected NSCLC patients and found that K-ras codon 
12 point mutations were strongly associated with unfavorable prognosis (Slebos et al., 1990).  
These patients also demonstrated shorter disease-free survival. 
In a study of 50 surgically resected patients with non-small cell lung cancer, there were 
no differences in survival on the basis of K-ras status in tumor, however there was a significantly 
worse survival observed in patients with K-ras mutation in serum. (Ramirez et al., 2003). 
Another recent study of serum of patients with advanced non-small cell carcinoma preparing to 
receive platinum-based chemotherapy showed no correlation between the presence of K-ras 
mutations and objective response rate, progression-free and overall survival (Camps et al., 2005). 
An Eastern Cooperative Group (ECOG) study (E4592) examined the tumor specimens of 
patients with Stage II and respectable Stage IIIA (N2) disease who were being entered onto a 
parent treatment study.  Of the 189 assessable tumors studied for K-ras mutations, there were no 
significant differences in survival based on K-ras mutations in any group by baseline 
characteristics.  Marginally statistically significant findings for survival by K-ras mutation were 
seen in patients randomized to the chemotherapy arm of the study, patients with good 
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 performance status, patients with weight loss, and patients with nodal stage of N1 (Schiller et al., 
2001). 
2.6.3. K-ras Gene Mutations in Sputum 
Mao et al. examined archived sputum specimens from the Johns Hopkins Lung Project for ras 
and p53 gene mutations, using a PCR-based assay. In 8 of 10 patients, an identical mutation 
identified in the primary tumor was seen in at least one sputum sample. The earliest of these was 
seen one year prior to a diagnosis of lung cancer (Mao et al., 1994).  Yakubovskaya et al. 
detected K-ras mutations in 60 % of lung tissue samples and 47% sputum samples from patients 
with NSCLC, as compared with 10% and 12.5% of respective controls (Yakubovskaya et al., 
1995).  These early studies indicated the potential use of ras mutations in sputum as a biomarker 
for exposure and early detection of lung cancer for those at high risk. 
K-ras mutations can be detected in the sputum of patients with adenocarcinoma of the 
lung more than one year prior to clinical diagnosis (Kennedy & Hirsh, 2004), and have been 
found in subjects who do not subsequently develop lung cancer. Zhang et al. studied  codon 12 
K-ras mutations in the tumor and corresponding sputum sample from lung cancer patients. K-ras 
mutations were seen in 54.5% (12) of lung tumors and 45.5% of sputum (10), with nine patients 
showing an identical mutation in both the tumor and matched sputum sample (Zhang et al., 
2003). 
A study of sputum samples obtained from high risk individuals without lung cancer in 
China who were exposed to smoky coal emissions showed frequent p53 gene mutations and to a 
lesser degree K-ras mutations.  Subjects in this study, many of whom were smokers, are 
anonymous so it is not possible to follow the association of these mutations and lung cancer 
development (Keohavong et al., 2005).   
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A recent study examined K-ras and p16INK4A mutations in tumor tissue and sputum of 50 patients 
with NSCLC.  The rate of detecting molecular changes in the sputum (48%) was similar to the 
cytological abnormalities - atypical and/or malignant cells (42%).  A combined molecular and 
cytological analysis used in these samples yielded even more abnormal cases.  Interestingly, K-
ras mutations and p16 INK4A hypermethylation were infrequently detectable in the same patient 
supporting their combined use in sputum molecular assay (Destro et al., 2004). 
2.6.4. Molecular Analysis 
Keohavong et al. describe a method of analysis for p53 and K-ras mutations where epithelial 
cells are selectively taken by using a laser capture microdissection microscope and PCR and 
denaturing gradient gel electrophoresis (DGGE)  (Keohavong et al., 2003).  The methods used 
for molecular analysis in this study, a combination of PCR, mutant allele enrichment (MAE), and 
DGGE, are completely described in the methods section.  
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3. Methods 
 
3.1. Eligibility and Recruitment of Subjects 
This study recruited 154 men and women 50-79 years old, who are at-risk for lung cancer by 
virtue of current or past cigarette smoking history, and are enrolled in the Pittsburgh Lung 
Cancer Screening Study (PLuSS).  PLuSS is Project 5 of the Pittsburgh Lung SPORE (IRB# 01-
1171). The timeframe between entry into the PLuSS study and entry onto this study was 
approximately three months. Eligible participants were a subset of those who are enrolled on the 
PLuSS Study.  The PLuSS Study enrolled 3755 participants between January 2002 and April 
2005.  PLuSS participants had baseline questionnaire data collected, underwent pulmonary 
function testing, baseline blood collection, and were screened for lung cancer using low-dose 
lung CT scanning at baseline and one year later.  
3.1.1. Eligibility Criteria 
Eligibility criteria for this study were the same as for the PLuSS study and included: 1) age 50-
79 years, 2) no past personal history of lung cancer, 3) history of smoking 11 or more cigarettes 
per day for at least 25 years and, if quit, quit no more than 10 years before study entry, 4) non-
participation in other lung cancer screening studies, 4) no self-reported chest CT within one year, 
and 6) written and signed informed consent.  These criteria effectively exclude women of 
childbearing potential.  However, because of the small potential fetal risk associated with 
diagnostic x-ray procedures, the investigators reminded women who could possibly be pregnant 
(e.g., late menses) to postpone the screening lung CT and therefore postpone the sputum 
collection.  HIV serostatus was not evaluated. 
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 3.1.2. Human Subjects Protection 
The research study was approved by the University of Pittsburgh Institutional Review Board 
(IRB) for Human Subject Research prior to participant recruitment. All specimens were 
identified only by PLuSS study identification number to ensure confidentiality. The researchers 
who performed the cytologic and DNA analyses only had access to the study identification 
numbers and could not link them with any identifying information. 
3.1.3. Recruitment 
Potential participants were approached for entry onto the sputum collection study by PLuSS 
staff, at the time of initial evaluation.  Interested individuals were asked to provide two 3-day 
pooled sputum specimens across six consecutive days, collected at home, after being provided 
with written instructions, a consent form, and two containers.  The containers contained 30 ml of 
CytoLyt®, a methanol-based fixative (Cytyc Corp., Boxborough, MA, U.S.A.). Written 
informed consent was obtained from each participant. Subjects who agreed to participate 
returned their specimens to the Principal Investigator on the day of their initial screening CT 
scan. 
This study aimed to recruit 300 participants who were enrolled in the parent PLuSS 
study.  Unfortunately, PLuSS ended recruitment of new participants in April of 2005, thus 
recruitment to this study was concluded after 154 subjects were enrolled.   
 
3.2. Laboratory Methods 
3.2.1. Preparation and examination of slides 
Samples were first processed by centrifuging the specimen for 10 minutes, then decanting the 
supernatant. A stock solution of 2.5 G Dithiothreitol (DTT) and 30 ml of CytoLyt® was 
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 prepared and approximately 2 ml of the solution was added to each specimen to achieve 
mucolysis.  Next, the specimens were vortexed to break up the mucus and CytoLyt® was added 
to each specimen. Again the specimens were centrifuged for 10 minutes to concentrate the 
cellular material.  The supernatant was decanted and the specimens vortexed to dislodge the cell 
pellet.  Finally, two drops of the specimen were added to a vial of PreservCyt® solution.  Slides 
were then prepared as monolayers using ThinPrep® protocol according to the manufacturer’s 
recommendation (ThinPrep® 2000 System Operators Manual, Cytyc Corporation).  The fixed 
slides were stained manually using the Papanicolaou method.  Slides were screened for adequacy 
by cytotechnologists in the Cytology Department at UPMC Presbyterian Hospital and read by 
experienced cytopathologists.  Several (31) of the slides were read by a second cytopathologists 
at the University of Pittsburgh who was blinded to the results from the first reading.   
 
3.3. Examination of Slides by Secondary Investigators 
One hundred forty three slides were also sent to the University of Colorado for review by 
secondary investigators.  These investigators were blinded to the results of the University of 
Pittsburgh cytopathologists. 
The Colorado Lung SPORE researchers utilized the following criteria to assess sputum 
specimens for adequacy, determine inflammation severity, and determine the cytologic 
diagnosis.  These criteria are based upon criteria established in the 1960s and 1970s by 
Saccomanno and colleagues (Kennedy et al., 1996; Kennedy et al., 1999; Prindiville et al., 
2003). 
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 3.3.1. Specimen Adequacy 
Adequacy of sputum specimens was assessed as either satisfactory, with 100 or more histiocytes 
present in review quadrant(s) OR presence of Curschmann’s spiral; less than optimal, with 50 to 
90 histiocytes present in review quadrant(s) AND 5 + empty fields in quadrant(s); and 
unsatisfactory, with less than 50 histiocytes present in review quadrant(s) AND 5 + empty fields 
in quadrant. 
3.3.2. Inflammation Severity 
Inflammation was defined as percentage of cells obscured by acute or chronic inflammatory cells 
and is assessed as insignificant, with less than 5 % cells obscured; mild, with 5 to 25% of cells 
obscured; moderate, with 25-75% of cells obscured; and severe, more than 75% of cells 
obscured. 
3.3.3. Dysplasia Grade Criteria 
The following criteria described the degree of dysplasia: Mild atypia is described by: (a) cells 
vary in size, (b) nuclei vary in size and nuclear/cytoplasmic (N/C) ratio may vary slightly, (c) 
nuclei round to oval, 2 halves of nucleus are mirror images, (d) cytoplasm may be acidophilic, 
(e) distinct cytoplasmic border has “cookie cutter sharp” appearance.  Moderate atypia is 
described by: (a) cells vary moderately in size and may be somewhat smaller than found in mild 
atypia, (b) nuclei vary slightly in size with variation in N/C ratio, (c) nuclear lobulations, 
crevices, and nodules are present, (d) variation from cell to cell in size and shape, (e) cytoplasm 
dense, acidophilia predominates, (f) nuclear material may show hyperchromasia with more 
stippled-like chromatin pattern, (g) increased number of atypical cells, (h) nucleus has unequal 
halves (not mirror images).  In transition from moderate to severe (marked) atypia, the cytoplasm 
may become canary yellow.  Severe (Marked) atypia is described as: (a) cells vary markedly in 
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 size and shape, (b) nuclear pleomorphism, coarse chromatin hyperchromatic, (c) N/C ratio varies 
with extremes, (d) hyperchromasia may be present with chromatin condensation along nuclear 
envelope, (e) acidophilic cytoplasm predominates, (f) single cells predominate, (g) nucleus may 
follow shape of cytoplasm. 
3.3.4. Cytologic Diagnosis 
Each specimen was assigned to one diagnostic criterion: no significant epithelial abnormalities, 
regular metaplasia, mild atypia, moderate atypia, severe (marked) atypia, carcinoma in situ, and 
invasive carcinoma.  Invasive carcinoma types are assigned as squamous cell, large cell 
carcinoma, adenocarcinoma, or small cell carcinoma. 
 
3.4. K-ras Mutations 
Forty eight samples were examined for the presence of mutations at Codon 12 of the K-ras 
oncogene by investigators at the University of Pittsburgh utilizing a combination of PCR, MAE, 
and DGGE. 
3.4.1. Overview 
DNA was extracted from each sputum sample.  An aliquot was screened for mutations by simple 
polymerase chain reaction (PCR) with KI1-1 and PKB primers, followed by denaturing gradient 
gel electrophoresis (DGGE) analysis. This direct method can detect mutations that are present at 
a mutant fraction of at least 5-10% over a nonmutant background (Keohavong et al., 2004). 
The current study also used a specially designed series of PCR reactions to enhance detection of 
low frequency codon 12 K- ras gene mutation. Using a second DNA aliquot, this special 
procedure added two so-called mutant allele enrichment (MAE) PCR steps.  The MAE PCR used 
a specially designed primer followed by a restriction endonuclease reaction to selectively cut 
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 DNA PCR products derived from wildtype K-ras DNA. The more elaborate PCR + MAE + 
DGGE procedure can detect K-ras mutations present at a mutant fraction of 10-4- 10-5.  
Sequence-based methods were used to identify mutant alleles detected with DGGE (see below).   
The MAE + DGGE assay has two main steps.  In the first step, there is enrichment of 
mutant alleles present at low fraction among the wild-type allele in each DNA sample.  This 
selective enrichment is based upon the presence or absence of mutations within a short sequence 
of the template fragment, such as the sequence of two adjoining codons, happening to correspond 
to the site for a restriction enzyme.  A wild-type allele is expected to be cleaved into shorter 
fragments by the corresponding restriction enzyme.  A mutant allele will not be cleaved.  The un-
cleaved mutant allele can be separated from the cleaved wild-type allele by gel electrophoresis. 
The sequence of the human K- ras gene codon 12 and its flanking codons does not correspond 
naturally to any restriction enzyme site.  The sequence of codons 12 and 13, 5’-CGT GGC-3’ 
does correspond to the restriction site for BanI endonuclease (5’-GGT GCC-3’), if the G at the 
middle of codon 13 were to be replaced with a C.  Therefore, the special PCR primer used in the 
MAE procedure is designed to introduce the G to C substitution needed to generate the BanI 
endonuclease site in the amplified fragments. 
Step-by-step, the mutant allele enrichment is carried out by PCR amplification of the 
template fragment from genomic DNA to introduce the restriction enzyme site, i.e. Ban I 
restriction enzyme. The amplified product is treated with BanI endonuclease to digest the wild-
type allele.  To further enrich the fraction of mutant alleles in each DNA sample, this step is 
repeated once.  Then the un-cleaved mutant alleles are purified by gel electrophoresis from each 
DNA sample and further characterized by DGGE.   
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 DGGE separates duplex DNA fragments differing from each other by only a single point 
mutation.  A duplex DNA fragment must contain two contiguous regions, a high and a low 
temperature melting domain, in order to be suitable for analysis by DGGE.  If such a structure 
does not occur naturally, an artificially high temperature melting domain must be added using 
PCR (Keohavong et al., 1997). 
3.4.2. Procedure 
Half of each sputum sample in Saccomanno’s solution was centrifuged.  The cell pellet was 
washed twice with phosphate-buffered saline, resuspended in a lysis buffer (10mM Tris, pH 7.4, 
0.5% SDS, 150 M NaCl, 100 mM EDTA) and digested with RNase A1 (10mg/ml, at 37°C for 2 
hours) and proteinase K (20 µg/ml, at 37°for 4 hours).  DNA was recovered by phenol-
chloroform extraction and ethanol precipitation.  The DNA was resuspended in water and kept at 
-20°C (Keohavong et al., 2004). 
For DNA amplification, 10 µl of DNA extracted from each sputum specimen was used in 
a 50 µl reaction mixture containing 10mM Tris-HCl, pH 8.3, 1.5 mM MgCl2, 50mM KCl, 100 
µM dNTP, 0.5 µM each primer, and 2.5 units of Taq DNA polymerase (PerkinElmer, CT). The 
first round of PCR was carried out for 12 cycles (94ºC/1 min, 53ºC/2 min, and 72ºC/2min) using 
the primers KI1-1 (sense), 5’-TATTATAAGGCCTGCTGAAA-3’, and PKB (antisense), 
5’AGGCACTCTTGCCTACGGCA-3’.  The PCR products were diluted 10-fold with BanI 
restriction enzyme buffer and digested with 20 units BanI for 3 hours at 37ºC under the 
conditions described by the manufacturer (New England Biolab,  MA).  The DNA was then 
purified from the mixture using a PCR-purification kit (Promega Corp. Madison WI) and 
recovered in 50 µl of PCR  
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 reaction mixture containing 45 µM dNTP, 0.5 µl of [α-32P]-dCTP (3000 Ci/mmol, New England 
Nuclear, Boston, MA) 1 µM primer PKB, and 1 µM PKGC, 5’-
GCCGCCTGCAGCCCGCGCCCCCCGTGCCCCCGCCCCGCCGCCGGCCCGGCGCCTATA
AGGCCTGCTGAAAATG-3’, and 2 units Taq. After 35 cycles, a 20 µl-aliquot of the mixture 
was diluted to 250 µl 1 X BanI buffer, and digested with 20 units BanI at 37ºC for 3 hours.  The 
DNA was recovered by ethanol precipitation and migrated through a 10% polyacrylamide gel 
(bis/acryl, 1/19).  The gel was exposed against X-ray film.  The position of the DNA in the gel 
was located by superimposing the autoradiogram on the gel. For DGGE analysis, a portion of the 
gel containing DNA fragment resistant to BanI digestion was excised from the gel and directly 
transferred into the wells of a denaturing gradient gel which consisted of a 12.5% 
polyacrylamide (bis/acryl, 1/37.5) containing a 30 to 45% gradient of denaturants (urea and 
formamide).  The gel was electrophoresed for 12 hours under, dried, and subjected to 
autoradiography.  Mutant, alleles were isolated from the gel and characterized by sequencing 
(Keovahong et al., 1997). 
 
3.5. Statistical Considerations 
3.5.1. Aims of Study 
The first aim was to evaluate the adequacy of sputa collected within the context of the PLuSS 
Study.  Specifically, this study aimed to determine the proportion of all sputum samples 
containing adequate amounts of cytologic material from the lower airways.  The experience of 
the Colorado Lung SPORE (Kennedy et al., 1996) indicated that they were able to collect an 
adequate sputum sample 70 percent of the time.  We expected to collect adequate sputum 
samples at a similar rate, so we tested the null hypothesis that our adequacy rate was > 70% vs. 
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 the alternative that the rate was < 70% using a one-sample binomial test with a one-sided value 
not to exceed .05.  If we observed 300 subjects, we would have a power of .95 to detect a rate as 
low as 60% and a power of .76 to detect a rate of 62.5%.  The 95% confidence interval 
containing this proportion would range between 65% and 75%. 
Our second aim was to determine whether mean forced expiratory volume in the first 
second (FEV1) was associated with cytologic abnormality in sputa collected from PLuSS 
participants.  A sample size of 154 is expected to provide 107 usable sputum samples.  In the 
Colorado Lung SPORE study, 28% of sputum samples showed at least moderate dysplasia.  
Applying this proportion, we expected to identify 30 subjects with at least moderate dysplasia 
and 77 subjects with either normal cytology or cytologic abnormality less severe than moderate 
dysplasia.  Based upon the results of pulmonary function studies of the first 260 current and ex-
cigarette smokers, the FEV1 was 82 percent of predicted (standard deviation 20%).  Originally 
we had planned to accrue 300 subjects, with approximately 210 specimens being adequate for 
interpretation. A study comparing 60 and 150 subjects with and without cytologic abnormality 
has enough power (β = 0.20) to detect an 8.6 percentage point difference in mean FEV1, 
expressed as a percentage of the expected value (t-test, two-sided, α = 0.05).  
Our third aim was to determine the association of other baseline measures with dysplasia.  
For continuous measures the approach is similar to that described in our second aim.  For 
discrete measures, we used chi-square analyses with Fisher’s exact test to measure associations. 
For our fourth aim we provided estimates and confidence intervals for the prevalence of 
K-ras mutations in persons at risk for lung cancer.  
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 For our fifth aim we constructed ROC curves for with FEV1 as a predictor of (at least 
moderate) dysplasia and reported sensitivity and specificity of the analysis at FEV1 % of 
predicted cut-points of 50%, 60%, 70%, 80% and 90%.  
3.5.2. Statistical Software 
All of the analyses were carried out using SAS System 8e for Windows (Release 8.02 TS Level 
02M0, © 1999-2001 SAS Institute Inc., Cary, NC, USA). 
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4. RESULTS 
 
4.1. Characteristics of Individuals Who Were Asked to Participate in the Sputum 
Collection Study, Those Who Accepted Participation, and Those Who Enrolled in the 
Study 
Seven hundred seventy PLuSS participants were offered participation in this study.  Of those, 
321 (41.7%) initially accepted participation.  Of the original 770 who were offered participation 
in the study, only 20% returned sputum specimens (N=154).  Table 1 shows the characteristics of 
those individuals.  
 
Table 1.  Characteristics of those PLuSS participants who were offered participation in sputum collection 
study, those who accepted participation, and those who returned sputum specimens. 
 Offered   Accepted   Returned 
Risk factor group N  N 
PCNT 
[1] 
p-value 
[4]  N 
PCNT 
[2] 
p-value 
[4] 
PCNT 
[3] 
p-value 
[4] 
All 770  321 41.7   154 48.0  20.0  
            
Gender            
  Male 387  171 44.3 0.1600  95 55.6 0.0037 24.6 0.0015 
  Female 383  150 39.2   59 39.3  15.4  
Age            
  50-59 448  187 41.8 0.9900  76 40.6 0.0049 17.0 0.0359 
  60-69 256  107 41.8   60 56.1  23.4  
  70-79 66  27 40.9   18 66.7  27.3  
Smoking            
  Current 454  225 49.6 0.0001  105 46.7 0.4724 23.1 0.0093 
  Ex 316  96 30.4   49 51.0  15.6  
Productive Cough            
  No 378  90 23.5 0.0001  40 44.9 0.5014 10.6 0.0001 
  Yes 392  231 59.1   114 49.4  29.2  
1.  Number accepting sputum collection cup, expressed as a percentage of PLuSS participants offered a sputum collection cup. 
2. Number returning sputum collection cup, expressed as a percentage of PLuSS participants accepting a sputum collection cup. 
3. Number returning sputum collection cup, expressed as a percentage of PLuSS participants offered a sputum collection cup. 
4. Statistical significance of risk factor group differences in the percentages accepting or returning a sputum collection cup, 
based on chi-square test. 
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 Of PLuSS participants that were offered participation in this sputum collection study, 
there were no differences in acceptance rates between men and women or between age groups.  
Current smokers more often accepted participation (P < 0.001), and individuals who admitted 
having a productive cough more often accepted participation (P < 0.001).  Of PLuSS participants 
who agreed to participate in the sputum collection study and who were given containers to take 
home,  men more often than women returned the samples (P = 0.0037), and older people more 
often (P = 0.0049) returned the samples.  Of all PLuSS participants who were asked to 
participate in the sputum collection study, those who eventually returned samples were more 
likely to be male (P = 0.0015), older (P = 0.0359), current smokers (P = 0.009), and have a 
productive cough (P = < 0.001).  The baseline characteristics of the PLuSS participants who 
participated in the sputum collection study are found in Table 2. 
 
Table 2.  Baseline characteristics of sputum collection study participants N = 154  
   N % 
Gender    
  Male 95 61.7 
  Female 59 38.3 
Age    
  50-59 76 49.4 
  60-69 60 39.0 
  70-79 18 11.7 
Smoking    
  Current 105 68.2 
  Ex 49 31.8 
Average Cigarettes/Day    
  1-19 46 29.9 
  20-29 75 48.7 
  30+ 33 21.4 
MD Diagnosis    
  Asthma 25 16.2 
  Bronchitis 27 17.5 
  Emphysema 21 13.6 
Race    
  White 144 93.5 
  Black 8 5.2 
  Other 2 1.3 
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 Table 2 Cont’d 
Marital Status    
  Married 98 63.6 
  Prior marriage 43 27.9 
  Never married 13 8.4 
Education    
  11 Years or less 7 4.5 
  12 Years or completed HS 38 24.7 
  Post HS or some College 61 39.6 
  College graduate or postgraduate 48 31.2 
Symptoms    
  Phlegm 114 74.0 
  Cough 67 43.5 
  Wheeze 67 43.5 
  Dyspnea 79 51.3 
  Edema 26 16.9 
  Wt Loss 2 1.3 
 
The characteristics of age, gender, and productive cough could possibly confound the association 
between smoking and whether PLuSS participants accepted participation in the sputum 
collection study and whether they eventually participated. We used logistic regression to identify 
which of these four factors (gender, age, smoking, and productive cough) maintain significance 
when mutually adjusted for the other factors.  In the group that was initially offered participation 
in the sputum collection study (N = 770), the characteristics of current smoking (p = 0.002) and 
having a productive cough (p = < 0.001), were significant predictors of accepting participation.  
Being male appeared to be a predictor, although this was not statistically significant at alpha 
level 0.05 (p = 0.08).  In those PLuSS participants who accepted participation in the sputum 
collection study (N = 321), gender (p = 0.01) and age (p = 0.01) were predictive of returning a 
specimen.  Finally, of all PLuSS participants who were offered participation in the sputum 
collection study (N = 770), male gender (0.001) and having a productive cough (p = < 0.001) 
were predictive of whether the participants would return the sputum sample.   Table 1 shows that 
that age, gender, smoking, and having a productive cough are individual factors associated with 
returning a sputum sample in this study.  When these four factors are considered jointly in 
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 logistic regression, gender and having a productive cough were shown to have independent and 
statistically significant association with returning a specimen and cannot be considered to have 
occurred by chance.   
We stratified the data shown in Table 1 into two groups – those PLuSS participants who 
reported having a productive cough at baseline and those who reported not having a productive 
cough at baseline, to examine whether the determinants of age, gender, and smoking status were 
independent of having a productive cough.  Tables 3 and 4 show the characteristics of those 
participants who accepted and eventually returned sputum specimens stratified by whether or not 
they reported having a productive cough.  Gender is related to returning a sputum sample and 
this relationship is not entirely related to having a productive cough, as the relationship is 
retained in the stratified data.  Smoking is related to returning a sputum sample when expressed 
by percentage of people offered participation, but stratifying the data by productive cough 
reduces the magnitude this association. The association that did exist between smoking and 
returning a sputum sample is no longer statistically significant in either stratum.  This may be 
because smokers are more likely to have a cough.  Older age is associated with returning a 
sample in participants having a productive cough. 
 
Table 3.  Characteristics of those PluSS participants reporting not having a productive cough who were 
offered participation in sputum collection study, those who accepted participation, and those who returned 
sputum specimens 
  Offered   Accepted   Returned 
Risk factor group N   N 
PCNT 
[1] 
p-value 
[4]   N 
PCNT 
[2] 
p-value 
[4] 
PCNT 
[3] 
p-value 
[4] 
All 378  89 23.5   40 44.9  11.0  
            
Gender            
Male 190  52 27.4 0.0800  28 53.9 0.0453 14.7 0.0100 
Female 188  37 19.7   12 32.4  6.4  
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 Table 3 Cont’d 
Age            
50-59 228  58 25.4 0.1700  22 37.9 0.1800 9.7 0.4400 
60-69 120  28 23.3   16 57.1  13.3  
70-79 30  3 10.0   2 66.7  6.7  
Smoking            
Current 174  49 28.2 0.0500  22 44.9 0.9923 12.6 0.2300 
Ex 204  40 19.6   18 45.0  8.8  
            
1. Number accepting sputum collection cup, expressed as a percentage of PLuSS participants offered a sputum collection 
cup. 
2. Number returning sputum collection cup, expressed as a percentage of PLuSS participants accepting a sputum collection 
cup. 
3. Number returning sputum collection cup, expressed as a percentage of PLuSS participants offered a sputum collection 
cup. 
4. Statistical significance of risk factor group differences in the percentages accepting or returning a sputum collection cup, 
based on chi-square test. 
 
Table 4.  Characteristics of those PluSS participants reporting having a productive cough who were offered 
participation in sputum collection study, those who accepted participation, and those who returned sputum 
specimens 
  Offered   Accepted   Returned 
Risk factor group N   N 
PCNT 
[1] 
p-value 
[4]   N 
PCNT 
[2] 
p-value 
[4] 
PCNT 
[3] 
p-value 
[4] 
All 392  232 59.2   114 49.1  29.0  
            
Gender            
   Male 197  119 60.4 0.6206  67 56.3 0.0251 34.0 0.0308 
   Female 195  113 58.0   47 41.6  24.1  
Age            
   50-59 220  129 58.6 0.6283  54 41.9 0.0295 24.6 0.0299 
   60-69 136  79 58.1   44 55.7  32.4  
   70-79 36  24 66.7   16 66.7  44.4  
Smoking            
   Current 280  176 62.9 0.0193  83 47.2 0.2851 29.6 0.6989 
   Ex 112  56 50.0   31 55.4  27.7  
            
1. Number accepting sputum collection cup, expressed as a percentage of PLuSS participants offered a sputum collection 
cup. 
2. Number returning sputum collection cup, expressed as a percentage of PLuSS participants accepting a sputum collection 
cup. 
3. Number returning sputum collection cup, expressed as a percentage of PLuSS participants offered a sputum collection 
cup. 
4. Statistical significance of risk factor group differences in the percentages accepting or returning a sputum collection cup, 
based on chi-square test. 
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 4.2. Interpretation of Samples of Participants Entered in the Sputum Collection Study 
All of the 154 samples that were returned were interpreted by the chief of Cytopathology at the 
University of Pittsburgh.  One hundred forty three samples were also read by a cytopathologist 
affiliated with the University of Colorado Lung Special Project of Research Excellence 
(SPORE).  Eleven of the original 154 slides were missing from the lab at the time the slides were 
sent to Colorado.  All of the slides (N= 20) that were diagnosed as high grade dysplasia 
(moderate or severe atypia) by the University of Colorado cytopathologist were returned to the 
chief of Cytopathology at the University of Pittsburgh to be re-reviewed.  The original diagnoses, 
made at the University of Pittsburgh, were confirmed in all of these cases.  Of these twenty, only 
two were diagnosed at the University of Pittsburgh with any degree of atypia (both mild), fifteen 
showed squamous metaplasia and three were normal.  Inter-rater reliability between the 
Pittsburgh and Colorado readings is discussed later in this document. 
 
4.3. Assessment of Adequacy, Degree of Inflammation and Cytologic Diagnosis – University 
of Pittsburgh 
4.3.1. Assessment of Adequacy – University of Pittsburgh 
Of the 154 participants who provided samples, adequacy in eight was rated as unsatisfactory and 
no diagnosis was made in seven of these eight.  One hundred forty six (94.8 %) were adequate 
for interpretation. 
4.3.2. Degree of Inflammation – University of Pittsburgh 
Inflammation was noted in 22 samples (14%).  In all specimens where inflammation was noted, 
the description of inflammation was noted as acute. 
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4.3.3. Sputum Cytology Results – University of Pittsburgh 
Eight samples (5 %) were reported as having mild atypia, 89 (58 %) showed squamous 
metaplasia, and 50 (32 %) were reported as normal.  Thirty one (20%) of the original 154 
samples read at the University of Pittsburgh were reviewed by a second cytopathologist at the 
University of Pittsburgh, who was blinded to the results documented by the primary reviewer.  
Table 5 illustrates the agreement between the cytologic diagnoses of both reviewers (Kappa 0.65; 
95% CI 0.44- 0.88). 
 
Table 5.  Agreement between primary and secondary reviewers for cytologic diagnosis – University of 
Pittsburgh 
Secondary Reviewer 
Primary Reviewer Normal Sq Metaplasia Mild atypia Unreadable Total 
Normal 9 1 0 1 11 
Squamous metaplasia 2 11 2 0 15 
Mild atypia 1 0 1 0 2 
Unreadable 0 0 0 3 3 
Total 12 12 3 4 31 
 
Kappa 0.65 (95% CI 0.44 - 0.88)  
The criteria for Kappa values used to report agreement are: poor (< 0.2); fair (0.2 – 0.4); 
moderate (0.4 – 0.6); good (0.6 – 0.8); and very good (0.8- 1.0) (Altman, 1991).  Thus, there is 
evidence of moderate to good agreement between the two reviewers on the cytologic diagnosis 
of the specimens.  Bowker’s test of symmetry was used for this analysis.  This measure tests 
marginal homogeneity.  In this analysis, Bowker’s test statistic (chi-square with 1 df ) is 4.33;  P 
= 0.61 suggesting that the  marginals are homogeneous. 
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 4.4. Assessment of Adequacy, Degree of Inflammation, and Cytologic Diagnosis – 
University of Colorado 
4.4.1. Assessment of Adequacy – University of Colorado 
Adequacy in twenty seven (19%) samples was rated unsatisfactory and no diagnosis was made in 
24 of these 27.  One hundred sixteen (81%) were satisfactory, however 6 of these 116 were said 
to be less than optimal.   
4.4.2. Degree of Inflammation – University of Colorado 
Inflammation was rated as insignificant in 110 (77%), mild in 11 (8%), moderate in 1 sample, 
severe in 1 sample, and not assessed in 20 (14%). 
4.4.3. Sputum Cytology Results – University of Colorado 
Of the 119 samples that were satisfactory and were given a cytologic diagnosis, three samples 
(2.5%) were reported as having severe (marked) atypia, 17 (14%) with moderate atypia, and 32 
(27%) with mild atypia.  The terms atypia and dysplasia were used interchangeably in the 
reporting of these results.   Four samples (3%) were reported as having squamous metaplasia and 
63 (44 %) were reported as normal. 
4.4.4. Inter-rater Reliability-Cytologic Diagnosis 
Table 6 illustrates the inter-rater agreement for the 143 samples that were read at both the 
University of Pittsburgh and the University of Colorado.  Agreement between cytopathologists at 
these two centers was poor (Kappa 0.07; 95% CI 0.00- 0.14).  One hundred fifteen discordant 
pairs are seen, largely due to the frequent levels of the diagnostic categories of mild and 
moderate atypia and unreadable samples (Colorado readings) and the diagnosis of squamous 
metaplasia (Pittsburgh readings).  Bowker’s test of symmetry was highly significant (p < .0001), 
indicating that the marginals are not homogeneous. 
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 Table 6.  Agreement between specimens reviewed at the University of Pittsburgh and the Colorado Lung 
SPORE 
   Colorado 
 Normal Sq metaplasia 
Mild 
atypia 
Mod. 
Atypia Severe atypia Unreadable Total 
Pittsburgh        
Normal 19 1 11 3 0 9 43
Squamous metaplasia 43 2 16 13 2 10 86
Mild atypia 1 1 3 1 1 1 8
Moderate atypia 0 0 0 0 0 0 0
Severe atypia 0 0 0 0 0 0 0
Unreadable 0 0 2 0 0 4 6
Total 63 4 32 17 3 24 143
Kappa 0.07 (95% CI 0.00 - 0.14)  
 
Tables 7 and 8 show the inter-rater agreement for the same data, grouped by all types of atypia 
(Table 7) and by all abnormal cytologic readings (Table 8).  Again, agreement between the two 
University sites was poor in regards to cytologic diagnosis.  Bowker’s test of symmetry was 
statistically significant regardless of the manner in which the data were categorized (p < 0001). 
 
 
Table 7.  Agreement between specimens reviewed at the University of Pittsburgh and the Colorado Lung 
SPORE – All atypia grades 
Colorado 
  Normal 
Squamous 
metaplasia 
All 
atypia Unreadable Total 
Pittsburgh       
Normal 19 1 14 9 43 
Squamous metaplasia 43 2 31 10 86 
All atypia 1 1 5 1 8 
Unreadable 0 0 2 4 6 
Total 63 4 52 24 143 
Kappa 0.04 (95% CI - 0.03- 0.11) 
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 Table 8.  Agreement between specimens reviewed at the University of Pittsburgh and the Colorado Lung 
SPORE – All abnormal grades  
Colorado 
  Normal 
Squamous 
metaplasia 
and atypia Unreadable Total 
Pittsburgh      
   Normal 19 15 9 43 
   Squamous metaplasia and atypia 44 39 11 94 
   Unreadable 0 2 4 6 
   Total 63 56 24 143 
Kappa 0.06 (95% CI - 0.06 - 0.18) 
 
 
We excluded all specimens that were determined to be unreadable at either the University of 
Colorado or the University of Pittsburgh.  These data are presented in Table 9.  Since the 
frequency table is a 2 x 2 table, McNemar’s test of marginal homogeneity was used (chi-square 
with 1 df). This test was statistically significant (p < 0.001), again confirming that the marginals 
are not homogeneous. 
 
Table 9.  Agreement between satisfactory specimens reviewed at the University of Pittsburgh and the 
Colorado Lung SPORE – All abnormal grades 
  Normal 
Squamous 
metaplasia 
and atypia Total 
Pittsburgh     
   Normal 19 15 34 
   Squamous metaplasia and atypia 44 39 83 
   Total 63 54 117 
Kappa 0.02 (95% CI - 0.14-0.18) 
 
 
4.4.5. Inter-rater Reliability – Inflammation 
The University of Colorado cytopathologists rated inflammation in each sample using the criteria 
described above.  The University of Pittsburgh cytopathologists documented inflammation only 
when it was present and rated it as acute inflammation.  We examined all of the samples that 
both sets of investigators rated as adequate for interpretation or rated as inadequate but still 
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 provided a cytologic diagnosis, or an assessment of inflammation (N= 120).  For this analysis, 
inflammation was categorized as present or absent.  Table 10 shows these findings.    
 
Table 10. Assessment of agreement between reviewers at the University of Pittsburgh and the University of 
Colorado for assessment of inflammation 
Colorado 
Pittsburgh  Absent Present Total 
  Absent 96 7 103 
  Present 12 5 17 
  Total 108 12  120 
Kappa 0.26 (95% CI 0.02 – 0.50) 
 
 
The Kappa value is 0.26 (fair).  McNemar’s Test of marginal homogeneity (chi-square, 1 df) 
produced a P value of 0.25, suggesting marginal homogeneity. 
 
4.5. Aim 1 – Evaluation of the Adequacy of Sputum Specimens Collected with the Context 
of the PluSS Study 
Based upon the experience of the Colorado SPORE group, we expected that our rate of specimen 
adequacy would be 70% or greater. We tested the null hypothesis that specimens are satisfactory 
70% of the time, versus the alternative hypothesis that specimens are satisfactory more often 
than 70% of the time.  Of the 154 samples examined at the University of Pittsburgh, 146 (94.8%) 
were determined to be satisfactory (95% CI 91.3- 98.3).  We rejected the null hypothesis at an 
exact P-value < 0.001.  Of the 143 specimens that were sent to the Colorado SPORE 
investigators, 116 (81.1%) were determined to be satisfactory (95% CI 74.7 – 87.5). We rejected 
the null hypothesis at an exact P-value <0.001.  Our rate of specimen adequacy was greater than 
70% in readings from both the University of Pittsburgh and the University of Colorado. 
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 4.6. Aim 2 – Evaluation of the Association Between FEV1 and Cytologic Atypia 
The demographic characteristics of patients whose sputum slides were examined at the 
University of Colorado, grouped according to GOLD stages are reported in Table 11.  The 
characteristics of age, smoking dose in cigarettes per day, and reporting a diagnosis of 
emphysema or asthma appear to be associated with GOLD score in the 154 participants (Fisher’s 
exact test). 
 
Table 11. Demographic characteristics of patients grouped according to Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) staging 
GOLD Score 
    ALL  0  1  2  3 or 4  P
    N % N % N % N % N %   
Gender               
  Male 95 61.7 48 50.5 15 15.8 27 28.4 5 5.3 0.35 
  Female 59 38.3 32 54.2 6 10.2 14 23.7 7 11.9   
Age            0.00 
  50-59 76 49.4 52 68.4 8 10.5 12 15.8 4 5.3   
  60-69 60 39.0 25 41.7 10 16.7 18 30.0 7 11.7   
  70-79 18 11.7 3 16.7 3 16.7 11 61.1 1 5.6   
Smoking            0.14 
  Current 105 68.2 51 48.6 18 17.1 26 24.8 10 9.5   
  Ex 49 31.8 29 59.2 3 6.1 15 30.6 2 4.1   
Average 
Cigarettes/Day             0.04 
  1-19 46 29.9 23 50.0 8 17.4 10 21.7 5 10.9   
  20-29 75 48.7 46 61.3 10 13.3 15 20.0 4 5.3   
  30+ 33 21.4 11 33.3 3 9.1 16 48.5 3 9.1   
MD Diagnosis               
  Asthma 25 16.2 12 48.0 0 0 6 24.0 7 28.0 0.00 
  Bronchitis 27 17.5 13 48.2 2 7.4 8 29.6 4 14.8 0.38 
  Emphysema 21 13.6 6 28.6 2 9.5 9 42.9 4 19.1 0.02 
Race            0.58 
  White 144 93.5 72 50.0 20 13.9 41 28.5 11 7.6   
  Black 8 5.2 6 75.0 1 12.5 0 0 1 12.5   
  Other 2 1.3 2 2.5 0 0 0 0 0 0   
Marital Status             0.64 
  Married 98 63.6 49 50.0 13 13.3 29 29.6 7 7.1   
  Prior marriage 43 27.9 21 48.8 7 16.3 10 23.3 5 11.6   
  Never married 13 8.4 10 76.9 1 7.7 2 15.4 0 0   
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 Table 11 Cont’d 
Education             0.23 
  11 Years or less 7 4.5 5 71.4 0 0 1 14.3 1 14.3   
  
12 Years or completed 
HS 38 24.7 19 50.0 8 21.1 6 15.8 5 13.2   
  
Post HS or some 
College 61 39.6 28 45.9 8 13.1 20 32.8 5 8.2   
  
College graduate or 
postgrad 48 31.2 28 58.3 5 10.4 14 29.2 1 2.1   
Symptoms               
  Phlegm 114 74 54 47.4 15 13.2 33 28.9 12 10.5 0.06 
  Cough 67 43.5 35 52.2 10 14.9 14 20.9 8 11.9 0.25 
  Wheeze 67 43.5 30 44.8 7 10.5 22 32.8 8 11.9 0.09 
  Dyspnea 79 51.3 36 45.6 9 11.4 24 30.4 10 12.7 0.05 
  Edema 26 16.9 16 61.5 2 7.7 8 30.8 0 0 0.29 
  Wt Loss 2 1.3 0 0 0 0 2 100 0 0 0.16 
 
We performed analysis of variance to determine whether FEV1, expressed as percent of 
predicted, was associated with cytologic atypia in the 143 participants whose slides were 
examined at the University of Colorado. For this analysis, the four participants with the cytologic 
diagnosis of squamous metaplasia (N=4) were grouped with those whose samples were normal.  
Analysis of variance produced an F Value = 3.90, (3, 139 df; P > F = 0.01). Since the global 
statistical test indicates significant variation in mean FEV1% predicted across subjects grouped 
according to cytologic interpretation, we used the Bonferroni approach to identify significant 
pairwise contrasts, while accounting for the multiple comparisons. This approach uses t-tests to 
evaluate each of six possible pairwise contrasts at a nominal alpha 0.05/6 = 0.0083.  The 
comparison between FEV1 percent of predicted and participants having mild atypia and 
moderate or worse atypia was statistically significant, suggesting an association between 
worsening lung function and cytologic abnormality.  There was also a significant difference 
between the FEV1 percent of predicted in the participants whose samples that were unreadable 
and those with moderate or worse atypia.  Table 12 gives the means and 95% confidence 
intervals for these comparisons. 
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 Table 12. Means and 95% confidence intervals for FEV1 percent predicted by cytologic diagnosis (University 
of Colorado) – all specimens 
Diagnosis N Mean 95% CI 
Normal and squamous metaplasia 67 78.10 72.40 - 83.80 
Mild atypia 32 82.23 73.97 - 90.48 
Moderate atypia and worse 20 66.38 55.94 - 76.82 
Unreadable 24 83.49 73.96 - 93.02 
TOTAL 143     
 
After excluding the unreadable samples, we performed analysis of variance to determine whether 
FEV1, expressed as percent of predicted, was associated with cytologic atypia in the remaining 
119 participants whose slides were given a cytological diagnosis at the University of Colorado. 
Analysis of variance produced an F Value = 4.59, (2, 116 df; P > F = 0.01). Since the global 
statistical test indicates significant variation in mean FEV1% predicted across subjects grouped 
according to cytologic interpretation, we used the Bonferroni approach at a nominal alpha = 
0.05/3 = 0.0166 to identify significant pairwise contrasts, while accounting for the multiple 
comparisons.  The comparison between FEV1 percent of predicted and participants having mild 
atypia and moderate or worse atypia was again statistically significant, and there was also a 
significant difference in the means between the participants with cytologic diagnosis of normal 
and squamous metaplasia and those with moderate or worse atypia.  This again suggests an 
association between worsening lung function and cytologic abnormality.  Table 13 gives the 
means and 95% confidence intervals for these comparisons. 
 
Table 13. Means and 95 % confidence intervals for FEV1 percent predicted by cytologic diagnosis (University 
of Colorado) – including only specimens with cytologic diagnosis 
Diagnosis N Mean 95% CI 
Normal and squamous metaplasia 67 78.10 72.55 - 86.65 
Mild atypia 32 82.23 74.20 - 90.25 
Moderate atypia and worse 20 66.38 56.23 - 76.53 
TOTAL 119   
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 The statistically significant categories in this analysis of variance remained unchanged after 
removing the four participants whose cytologic reading was squamous metaplasia.  This analysis 
was run using SAS Proc ANOVA and verified using Proc GLM which produced the same 
results. 
 
4.7. Aim 3 – Association Between Cytologic Atypia and Baseline Measures 
The demographic characteristics of patients whose sputum slides were examined at the 
University of Colorado, grouped according to sputum cytologic diagnosis of “normal or 
squamous metaplasia”, and “atypia” are reported in Table 14.  In this group (N = 143), two 
variables appear to be associated with the cytologic diagnosis of atypia (chi-square test): having 
symptoms of dyspnea (P = 0.02) and being a current smoker (P = 0.03). 
 
Table 14. Baseline characteristics by sputum cytological reading – Denver N = 143 
   ALL Unreadable 
Normal 
and 
Squamous 
Metaplasia 
Atypia- 
all 
grades   
   % % % % P 
  N=143 N=24 N=67 N=52  
Gender        
  Male 61.5 62.5 64.2 57.7 0.77 
  Female 38.5 37.5 35.8 42.3   
Age        
  50-59 49.7 54.2 40.3 59.6 0.26 
  60-69 38.5 33.3 47.8 28.9   
  70-79 11.9 12.5 11.9 11.5   
Smoking        
  Current 67.8 45.8 70.2 75.0 0.03 
  Ex 32.2 54.2 29.9 25.0   
Average Cigarettes/Day       
  1-19 28.7 20.1 34.3 25.0 0.32 
  20-29 49.6 58.3 40.3 57.7   
  30+ 21.7 20.8 25.4 17.3   
MD Diagnosis       
  Asthma 16.8 8.3 14.9 23.1 0.24 
  Bronchitis 17.5 20.8 16.4 17.3 0.88 
  Emphysema 14.7 25.0 8.9 17.3 0.13 
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 Table 14 Cont’d 
         
Race        
  White 93.0 95.8 92.5 92.3 0.84 
  Other 7.0 4.2 7.5 7.7   
Marital Status       
  Married 62.2 66.7 61.2 61.5 0.90 
  Prior marriage 29.4 29.2 28.4 30.8   
  Never married 8.4 4.2 10.5 7.7   
Education        
  Completed HS or less 29.4 25.0 28.4 32.7 0.45 
  Post HS or some College 39.9 37.5 35.8 46.2   
  
College graduate or 
postgraduate 30.1 37.5 35.8 21.2   
Symptoms        
  Phlegm 74.1 75.0 76.1 71.2 0.82 
  Cough 41.9 33.3 40.3 48.1 0.44 
  Wheeze 45.5 37.5 38.8 57.7 0.08 
  Dyspnea 53.8 66.7 41.8 63.5 0.02 
 
To examine just those subjects whose cytologic category was normal and those diagnosed with 
atypia of any degree, we omitted those with cytologic diagnosis of “squamous metaplasia” and 
those whose specimens were deemed to be unsatisfactory (N= 115).  These results are displayed 
in Table 15.  Cytologic atypia in this analysis was associated with subjects who reported dyspnea 
(P = 0.01) and wheezing (P = 0.04), and possibly with age, with younger age being associated 
with cytologic atypia. 
 
Table 15. Baseline characteristics by sputum cytological reading of either normal or of any grade of atypia – 
Denver N=115 
   ALL Normal 
Atypia- all 
grades  
   % % % P 
  N=115 N=63 N=52  
Gender       
  Male 62.6 66.7 57.7 0.32 
  Female 37.4 33.3 42.3   
Age       
  50-59 47.8 38.1 59.6 0.06 
  60-69 40.0 49.2 28.9   
  70-79 12.2 12.7 11.5   
Smoking       
  Current 71.3 68.3 75.0 0.43 
  Ex 28.7 31.7 25.0   
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 Table 15 Cont’d 
Average Cigarettes/Day      
  1-19 30.4 35.0 25.0 0.16 
  20-29 47.8 39.7 57.7   
  30+ 21.7 25.4 17.3   
MD Diagnosis      
  Asthma 18.3 14.3 23.1 0.22 
  Bronchitis 17.4 17.5 17.3 0.98 
  Emphysema 13.0 9.5 17.3 0.22 
Race       
  White 92.2 92.1 92.3 0.96 
  Other 7.8 7.9 7.7   
Marital Status      
  Married 60.9 60.3 61.5 0.81 
  Prior marriage 29.6 28.6 30.8   
  Never married 9.6 11.1 7.7   
Education       
  Completed HS or less 30.4 28.6 32.7 0.19 
  
Post HS or some 
College 40.0 34.9 46.2   
  
College graduate or 
postgraduate 29.6 36.5 21.2   
Symptoms       
  Phlegm 74.8 77.8 71.2 0.42 
  Cough 44.4 41.3 48.1 0.46 
  Wheeze 46.9 38.1 57.7 0.04 
  Dyspnea 50.4 39.7 63.5 0.01 
GOLD Score      
 GOLD 0 47.9 50.8 44.2 0.57 
 GOLD 1 15.7 14.3 17.3  
 GOLD 2 27.0 28.6 25.0  
 GOLD 3 & 4 9.6 6.4 13.5  
 
We then stratified the analysis by current vs. former smokers and saw a similar pattern of 
association between age and cytologic diagnosis in each stratum, although stratum-specific 
associations were not statistically significant because of small sample sizes.  Current smokers 
with atypia were somewhat more likely to be younger than current smokers without atypia, but 
this association was not statistically significant at alpha 0.05 (Table 16). 
We examined whether that relationship between age and atypia was independent of 
smoking dose (average cigarettes smoked per day).  Relative to smokers without atypia, current 
smokers with atypia included a higher proportion of younger people (50 – 59 year olds) 
regardless of smoking dose (Table 17). 
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 Table 16. Cytologic diagnosis by age and smoking dose stratified by smoking status (current vs. ex-smoker) 
  
Current Smokers 
(N=82) P 
Ex-smokers 
(N=33) P 
  Normal % 
Atypia- all 
grades 
Normal 
% 
Atypia- all 
grades 
   N = 43 
N = 
39  N = 20 
N = 
13   
Average 
Cigarettes/Day  
1-19  39.5 25.6 0.28 25.0 23.1 0.55 
20-29  41.9 59.0  35.0 53.9   
30+  18.6 15.4  40.0 23.1   
  
Age        
50-59  44.2 64.1 0.12 25.0 46.2 0.52  
60-69  44.2 23.1  60.0 46.2   
70-79   11.6 12.8   15.0 7.7   
 
 
Table 17. Cytologic diagnosis by age within smoking dosage groups – Current smokers 
 Average Cigarettes/Day 
 1-19 20-29 30+ 
 N = 27 N = 41 N = 14 
Age Normal % Atypia % P Normal % Atypia % P Normal % Atypia % P 
50-59 29.4 60.0 0.09 55.6 65.2 0.90 50.0 66.7 0.63 
60-69 52.9 10.0  33.3 26.1  50.0 33.3  
70-79 17.7 30.0  11.1 8.7  0.0 0.0  
 
Age appeared to be independent of smoking dose intensity (Table 18). 
 
Table 18. Participants with normal cytology by age and average number of cigarettes smoked 
 Age 
 
N = 
24 
N = 
31 N = 8 
Average # of 
Cigarettes per 
day 50-59 60-69 70-79 
1 - 19 33.3 35.5 37.5 
20 - 29 45.8 35.5 37.5 
30 + 20.8 29.0 25.0 
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 4.8. Aim 4 – Prevalence of K-ras Mutations in Persons at Risk for Lung Cancer 
Forty-eight samples were examined for mutations in codon 12 of the K-ras gene.  Table 19 
shows the characteristics of these individuals. 
 
Table 19. Demographic characteristics of participants whose sputum was analyzed for detection of K-ras 
mutations  N=48 
  N % 
Gender    
 Male 35 72.9 
 Female 13 27.1 
Age    
 50-59 25 52.1 
 60-69 20 41.7 
 70-79 3 6.2 
Smoking    
 Current 29 60.4 
 Ex 19 39.6 
Average 
Cigarettes/Day  
 1-19 15 31.3 
 20-29 17 35.4 
 30+ 16 33.3 
Race    
 White 45 93.8 
 Black 2 4.7 
 Other 1 2.08 
 
We were interested in whether the characteristics of these 48 subjects differed from the entire 
group of 154.   Chi-square tests were performed to assess for differences in gender, age, race, 
smoking status, smoking dose, marital status, symptoms, pulmonary diagnosis, and Gold 
SCORE.  The subset of participants who had their samples analyzed for K-ras mutations differed 
from those who did not have their samples analyzed for K-ras mutations in the characteristics of 
gender, smoking dose, and marital status.  Table 20 contains these data.   
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 Table 20. Comparison of demographic variables and GOLD score between participants who had K-ras 
mutation analysis performed with those who did not 
  K-ras mutation analysis done 
  Yes % (N = 48) No % (N=106) P-value 
Gender      
  Male 72.9 56.6 0.05 
  Female 27.1 43.4   
       
Age 50-59 52.1 48.1 0.37 
  60-69 41.7 37.7   
  70-79 6.2 14.2   
       
Race White 93.8 93.4 0.50 
  Other 6.3 6.7   
Smoking status     
  Current 60.4 71.7 0.16 
  Ex 39.6 28.3   
Smoking dose     
  1-19 31.3 29.3 0.03 
  20-29 35.4 54.7   
  30+ 33.3 16.0   
Marital status     
  Married 75.0 58.5 0.01 
  Prior marriage 12.5 34.9   
  Never married 12.5 6.6   
Education      
  11 Years or less 4.2 4.7 0.70 
  
12 Years or completed 
HS 18.8 27.4   
  
Post HS or some 
College 43.8 37.7   
  
College graduate or 
postgrad 33.3 30.2   
Symptoms     
  Phlegm 72.9 74.5 0.83 
  Cough 45.8 42.5 0.70 
  Wheeze 41.7 44.3 0.76 
  Dyspnea 41.7 55.6 0.11 
  Edema 12.5 18.9 0.33 
  Weight loss 2.1 0.9 0.56 
Diagnosis      
  Bronchitis 12.5 19.8 0.27 
  Emphysema 8.3 16.1 0.20 
  Asthma 12.5 17.9 0.40 
GOLD Score    
 GOLD 0 56.3 50.0 0.50 
 GOLD 1 8.3 16.0  
 GOLD 2 25.0 27.4  
 GOLD 3 10.4 6.6  
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 4.9. Results of Analysis of Sample for K-ras Gene Mutations 
Seven (14.6 %) of the samples demonstrated K-ras gene mutations at codon 12  
(exact 95% CI 0.060 – 0.2787).  Table 21 summarizes the K-ras mutations identified in the 
epithelial cells taken from the sputum of 48 of the 154 participants.  Six of the seven mutations 
were G to A transitions, where a purine was replaced by a purine.  One was a transversion with a 
purine (G) being replaced by a pyrimadine (T).   Transversion mutations are the most common 
K-ras mutations seen in smokers and may be generated by carcinogens found in tobacco smoke  
(Vahakangas et al., 2001, Zhang et al., 2003).  In two of the samples with reported K-ras 
mutations, the findings could not be confirmed during repeat analysis. 
 
Table 21. Summary of subjects and codon 12 K-ras mutations 
Subject No. K-ras mutation 
   
3 K-ras codon 12: GGT to AGT 
5 K-ras codon 12: GGT to GAT 
10 K-ras codon 12: GGT to GAT 
18 K-ras codon 12: GGT to AGT 
20 K-ras codon 12: GGT to GAT 
27 K-ras codon 12: GGT to GTT 
38 K-ras codon 12: GGT to AGT 
 
Table 22 shows the cytologic diagnoses of the 7 samples with K-ras Mutations. 
 
Table 22. Participants with K-ras gene mutations and corresponding cytologic diagnosis 
 Cytologic diagnosis 
Participant Number Pittsburgh Denver 
3 normal mild atypia 
5 squamous metaplasia moderate atypia 
10 squamous metaplasia mild atypia 
18 squamous metaplasia mild atypia 
20 normal unreadable 
27 squamous metaplasia normal 
38 normal normal 
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 We performed Fisher’s exact test to determine whether there was an association between K-ras 
gene mutation status (positive or negative) and sputum cytologic diagnosis (Colorado SPORE 
readings). Table 23 shows these results.  There was no association between K-ras mutation status 
and cytologic diagnosis in these 46 subjects. 
 
Table 23. Association between sputum cytologic diagnosis and K-ras  mutation status 
  K-ras + K-ras -  
  N = 7 N = 39 P 
Unreadable 1 7 0.27 
Normal 2 21   
Mild atypia 3 5   
Moderate atypia or worse 1 6   
  7 39 46 
 
 
We examined K-ras mutation in relation to any atypia (Table 24) and in relation to any atypia, 
excluding unreadable specimens (Table 25).  Although the relationship between K-ras mutations 
and atypia was not statistically significant, when we included those subject with unreadable 
sputum cytology, participants with cytologic atypia were 2.7 times more likely to have the K-ras 
gene mutation than those with normal and unreadable findings (95 % CI 0.7 -10.8).  When the 
unreadable samples were excluded, participants with cytologic atypia were 3.1 times more likely 
to have the K-ras mutation (95 % CI 0.64 – 14.7). 
 
Table 24. Association between sputum cytologic diagnosis and K-ras mutation status 
  K-ras + K-ras -  
  N = 7 N = 39 P 
Normal and unreadable 3 28 0.19 
Atypia 4 11   
  7 39 46 
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 Table 25. Association between sputum cytologic diagnosis and K-ras mutation status – Readable specimens 
only N=38 
  K-ras + K-ras -  
  N = 7 N = 32  P 
Normal 2 21 0.19 
Atypia 4 11   
  6 32 38 
 
Using the Wilcoxon Rank Sum test, we tested the null hypothesis that there is no difference 
between FEV1 percent of predicted between the subjects who were K-ras gene mutation positive 
and those that were negative for the mutation, against the alternative hypothesis that there is a 
difference between the two groups. The Wilcoxon exact test gave a P-value = 0.54 (two-sided), 
therefore we did not reject the null hypothesis of no difference in FEV1 percent predicted 
between the two groups. 
 
4.10. Aim 5 – Sensitivity and Specificity of FEV1 as a Predictor of Atypia 
We constructed an ROC (Figure 1) curve with FEV1% predicted to distinguish (at least 
moderate) atypia.  We estimated sensitivity and specificity at FEV1 percent predicted cutpoints 
of 50%, 60%, 70%, 80%, and 90% (Table 26).  As sensitivity improves, specificity declines 
markedly. 
 
 
Table 26. Sensitivity and specificity of FEV1 percent of predicted to predict cytologic atypia 
FEV1 % of predicted Sensitivity Specificity 
50 33.6 94.9 
60 45.0 88.3 
70 45.0 70.2 
80 65.0 53.5 
90 90.0 27.3 
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Figure 1. ROC curve (AUC=0.66) describing the ability of FEV1% predicted to distinguish moderate or 
severe atypia (N=20) vs. normal, metaplasia, or mild atypia (N=99).  
Diamonds identify sensitivity and 1-specificity values associated with specified FEV1% predicted cut-points. 
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5. DISCUSSION 
 
5.1. Importance of the Study 
This study utilized a convenient method of sputum collection and employed a novel method for 
processing and making slides.  Most studies of sputum cytology in the early detection of lung 
cancer utilize the conventional method of slide preparation, whose limitations are described in 
this document.  In this study we showed that the ThinPrep® method may have increased the 
adequacy of our specimens over conventional preparation.  
This study also gave the PLuSS investigators pilot data with which to design a sputum 
collection protocol for patients continuing on the PLuSS extension study, which began 
recruitment in early 2006.  The PLuSS extension study is recruiting higher risk PLuSS 
participants for additional CT scan follow-up.   
Although recruitment to this sputum collection study was lower than hoped, we have 
demonstrated a possible association between lung function, measured by FEV1 percent of 
predicted, and cytologic abnormality in sputum.  We have also provided data on the adequacy of 
slides prepared by the Thin Prep® method and are the first group to use the ThinPrep® method 
to make sputum slides at the University of Pittsburgh Medical Center. 
 
5.2. Recruitment of Participants 
Participants for this study were recruited from the parent PLuSS study at the time of the initial 
visit for blood work and pulmonary function testing.  For our sputum collection study we did not 
formally record the reasons that PLuSS participants refused to participate in this study, or why 
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 once they agreed, they failed to return the samples.  Those participants who offered anecdotal 
information cited two common reasons for non-participation: inability to produce sputum, and 
the unpleasantness of the procedure in general, the latter being particularly common in the 
women that we spoke with.  Our data showing that men were more likely to return their 
specimens may reflect this attitude in women.  Several potential participants cited work 
schedules as prohibiting them from following the directions for the sputum collection procedure.  
Future studies may benefit from having knowledge about the reasons that men and women 
choose to participate in a home sputum collection study.  To increase the participation rate, we 
would have to work harder with persons who cannot easily produce a sputum specimen. 
 
5.3. Adequacy 
The adequacy rate of our samples was higher than that seen in the literature from the Colorado 
Lung SPORE.  Higher adequacy rates were demonstrated in the cytologic readings given by 
investigators at both the University of Colorado (81%) and at the University of Pittsburgh (95%).  
Since having a productive cough was associated with participation in our study, it is possible that 
our participants were self-selected on the basis of this characteristic, which makes producing a 
sample much easier.  Since participation in this study was not a mandatory part of the parent 
PLuSS study and no incentives were used, we may not have captured a representative sample of 
PLuSS participants.   
This study used a novel method for slide processing and preparation, ThinPrep®, which 
is associated with better overall specimen adequacy.  Our high rate of adequacy may also be 
associated with the use of the ThinPrep® method. 
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 5.4. Differences Between Cytologic Diagnosis made at the University of Pittsburgh and the 
University of Colorado 
This study utilized two Universities for evaluation of sputum cytology, the University of 
Pittsburgh and the University of Colorado.  The agreement in cytologic diagnosis between the 
two sites was low.  The University of Colorado Lung SPORE’s cytologic readings are associated 
in the literature with an increased risk for development of lung cancer (Prindiville et al., 2003).  
However, these readings may not be reproducible in other centers, as the criteria for 
interpretation are not consistent with those generally used by cytopathologists (personal 
communication S. Raab, 2005). 
For this study, we utilized the University of Pittsburgh readings to determine whether to 
notify patients of abnormal findings (moderate dysplasia or worse).  Using Pittsburgh readings, 
we found no atypia worse than mild (N = 8).  After the cytologic diagnoses from the University 
of Colorado were made, the slides were returned to us and those who were determined to be 
moderate or worse dysplasia, were once again read at our site.  None of these readings were 
confirmed by The University of Pittsburgh cytopathologist.  It was decided that even though 
these results were not confirmed, the patients diagnosed at the University of Colorado with 
moderate dysplasia or worse would be contacted by the Principal investigator for the PLuSS 
study, a physician, and offered a second sputum collection.   
Utilizing the readings from the University of Colorado in our analysis allowed us to 
perform comparisons on sputum cytologic atypia with baseline characteristics, including lung 
function, and K- ras gene mutation status.  Of importance was the observed association between 
FEV1 and atypia, although there was potential for selection bias in our participants. The 
secondary investigators who performed the K-ras analysis (University of Pittsburgh) and those 
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 performing the cytologic readings (University of Colorado) were blinded to each other’s 
findings. 
Unfortunately, we will not be able to determine the association between the University Of 
Colorado cytologic diagnoses and the development of lung cancer within the scope of this study. 
 
5.5. K-ras Mutations 
Only 48 of the 154 samples that were collected were analyzed for K-ras mutations.  The  
investigator performing the K-ras mutation analysis reported difficulty performing the analysis 
in many of the samples from this study.  When this study started, there were no  data available on 
DNA analysis of specimens collected in CytoLyt® collection fluid and processed using the 
ThinPrep® method (personal communication, D. Wilkinson, 2003). This study suggests that the 
ThinPrep® method may not be optimal for detecting gene mutations, and that further studies are 
needed to determine if this method of collection and processing is harmful to DNA.  Attempts to 
study hypermethylation of the P16 gene in these samples were unsuccessful, which has been the 
experience of investigators at the Lovelace Respiratory Research Institute, NM (personal 
communication S. Belinsky, 2004, 2006).  We are in the process of conducting a pilot study of 
sputum in participants entered in the PLuSS extension study.  This pilot study will compare the 
DNA in sputum samples collected in CytoLyt® with those collected in Saccomanno’s fixative (a 
solution of 50% ethanol and 2% carbowax).  Saccomanno’s fixative has long been the 
conventional method for collecting sputum, and is the method used in published literature of 
DNA analysis of sputum. Twelve participants will provide two samples, collected at home using 
the same technique as in this study, one in each type of fixative.  The specimens in CytoLyt® 
will be processed using the same methods as used in this study (previously described in the 
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 methods section).  The samples in Saccomanno’s solution will be processed by conventional 
preparation.  After processing, the cell pellets appear identical and the investigator will be 
blinded as to the collection method and identity of the subjects.  The investigator will study these 
samples for various molecular changes including K-ras mutations and gene hypermethylation. 
We recently received IRB approval for this pilot study and recruitment is underway.  Because the 
ThinPrep® method of sputum collection is becoming more widely used, this study is important 
since investigators are interested in comparing cytological findings with molecular markers for 
assessing lung cancer risk. 
 
5.6. Limitations 
Some of the limitations of this study include self selection by participants.  Our sample was older 
in comparison with PLuSS participants in general.  We had a largely male sample and 
participants were more likely to be current smokers. Sample size was also a limitation.  In a 
study as small as ours, even if we had reached our accrual goal of 300 participants, we could not 
compare cytologic atypia with incident or prevalent lung cancer.  Of our 154 participants, only 2 
were diagnosed with lung cancer during the period of this study. One of these participants had a 
sputum cytology reading of normal (Pittsburgh) and unsatisfactory (Colorado). The other 
participant was read as squamous metaplasia (Pittsburgh) and unsatisfactory (Colorado).  
Another limitation of this study was the uncertainty of whether the collection method we 
used would yield adequate DNA for molecular analysis.  No data were available on the DNA of 
samples collected in CytoLyt®.  This question still exists and a follow-up study is underway to 
investigate this issue. 
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 5.7. Conclusion 
This study showed that FEV1 expressed as percent of predicted was associated with moderate or 
worse sputum cytologic atypia, diagnosed at the University of Colorado.  PLuSS participants 
who participated in this study had lower FEV1 percent predicted with worsening sputum 
cytologic diagnosis.  This result partially validates the Colorado method for interpreting sputum 
cytology.  K-ras mutations appeared to occur more frequently in participants with atypia, 
although this relationship was not statistically significant.   
This study also showed a higher rate of sputum specimen adequacy than published in the 
literature, which may be due to the ThinPrep® technique used to process these samples and 
make the slides, and because our participants were more likely to report having a productive 
cough. 
 
5.8. Future Research 
A pilot study, previously described, is now underway to investigate which sputum collection and 
preparation method, conventional preparation, or the Thin Prep® method, is better for DNA 
analysis.  Results of that pilot study may better guide future studies of sputum for molecular 
markers.  The PLuSS extension study is collecting and banking sputum to be used in future 
studies.  It is hoped that the experiences of this study will help investigators as they go forward 
with the study of sputum cytology and molecular markers for early detection of lung cancer.  The 
lack of agreement between the cytologic readings at our two sites, suggests that there is a need 
for better consensus among cytopathologists about the terminology used to describe cytologic 
abnormalities seen in sputum.  As computer-assisted image cytometry approaches improve, 
quantitative cytology may prove to be an important tool for screening for individuals at high risk 
for lung cancer.
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APPENDIX A   
 
HOME SPUTUM COLLECTION PROCEDURE 
 
You will be collecting two sputum specimens, each obtained at home over a 3-day period for a total of six 
days.  Thank you very much for participating in this trial. 
 
 You should have received two sputum cups in an envelope or in a self-addressed mailer. 
 
 
WHAT IS SPUTUM? 
 
The mucus-like material that is expelled from the respiratory passages or the “breathing tubes” is 
called sputum.  A specimen is obtained by coughing up sputum from deep in the lungs and 
placing it in a bottle containing fixative.  This preserves the cells until they can be prepared for 
evaluation in the laboratory. 
 
Collection of the sputum requires you to produce a morning sputum specimen for three 
consecutive days.  It is important that you do not eat food or drink liquid prior to collecting your 
sputum. 
 
Please remember that sputum comes from deep coughing.  Please try to avoid contaminating this 
specimen with saliva or sinus drainage. 
 
 
To collect your sputum specimen: 
 
1. Upon going to bed, place the first sputum container at your bedside. 
 
2. Upon awakening in the morning, brush and rinse your mouth well with water (DO NOT 
USE TOOTHPASTE). 
 
3. Carefully remove the cap from the first sputum collection container. 
 
4. Sit at the bedside and take 3 slow deep breaths and exhale through pursed-lips. 
 
5. Breathe deeply a fourth time and forcefully cough.  Coughing should be from deep down 
in your chest and cough directly in the container.  You may find that bending forward 
slightly during the cough may help raise the sputum. 
 
6. Be sure to clear the sputum from the back of your mouth and throat.  Repeat the process 
three to four times until you feel that there is no more sputum coming up. 
 
7. Replace the cap tightly on the container. 
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8. Repeat steps 1-7 for three consecutive mornings for the first sputum collection container.  
Do not worry if you miss a day, just do it the following morning. 
 
9. After finishing the third collection day, please write the date on the affixed label and 
place the first sputum cup in the mailer. 
 
10. Remove the second sputum cup and repeat the process over again for the 3-day 
collection.  Again, do not worry if you miss a day, just do it the following morning. 
 
11. After finishing the third collection into the second sputum cup, please again write the 
date on the affixed label and place it on top of the first cup inside the mailer.  Seal the 
mailer and bring it with you to the PluSS Clinic or to the radiology department when you 
come for your screening CT scan.  If you have been instructed to mail the specimens,  
place the mailer in your mailbox for pick up. 
 
 
 
 
NOTE: If you are having difficulty producing a sputum sample upon awakening, you may find 
that sputum production is increased after inhaling the misty air in the shower.  If this is the case, 
feel free to first take a shower then collect your sputum specimen. 
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